Grande4587258
Posted - 11 hours ago
$RHHBY It’s Go Time !
LMDXWILLBOOM
Posted - 16 hours ago
$LMDX just so you guys are aware list of otc value $LZAGF $ADDYY $MBGAF $RHHBY $LKNCY Just hold Lumiradx we're fine!
LMDXWILLBOOM
Posted - 16 hours ago
$LMDX Not always! $rhhby $lzagy $mbgaf $adddf $lkncy all trade on otc! $SBNY is on expert market went from .0006 now $3.50. Who's to say Lumira will even stay on OTC? Just need that FDA and this collaboration to pop and we'll be in dollar world in no time!
DonCorleone77
Posted - 1 day ago
$RHHBY FDA approves Genentech's Alecensa for adjuvant treatment Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has approved Alecensa for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer, as detected by an FDA-approved test. Alecensa is now the first and only ALK inhibitor approved for people with ALK-positive early-stage NSCLC who have undergone surgery to remove their tumor. "With an unprecedented 76% reduction in the risk of disease recurrence or death versus chemotherapy, Alecensa significantly improves upon the standard of care for people with early-stage ALK-positive lung cancer," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "At Genentech, our goal is to give patients the best chance of cure by bringing effective, targeted treatments to early-stage disease before their cancer has spread. This approval brings us one step closer to achieving that mission."
Samishere
Posted - 1 day ago
$AMGN $CHRS $RHHBY Unfortunately phase I does absolutely nothing for shareholders,,,2 even by tomorrow,,ones next week
neofeudal
Posted - 1 day ago
$CHRS I am still running off fumes of Oldgrape's posting of this article. Very bullish pipeline news for Coherus. https://www.oncologypipeline.com/apexonco/ccr8-expectations $RHHBY $AMGN
ern1in
Posted - 1 day ago
$RHHBY Investment Ideas > $TGTX, BRIUMVI >>>>>> Best In Class CD20 & today's Veterans Affair Contract (sealed & delivered) ......
ern1in
Posted - 1 day ago
$RHHBY 5/18/3024 Adding more $TGTX 🦬🦬🦬🦬🦬 .... NEWS ! TG Therapeutics wins Veterans Affairs Contract for Multiple Sclerosis Drug BRIUMVI.
LMDXWILLBOOM
Posted - 2 days ago
$LMDX gotta love it! We are tangled with $rhhby so this info is just as important to us. PR will follow so maybe we'll get some news. 🫡🤞🤞🤞
DonCorleone77
Posted - 2 days ago
$RHHBY Genentech reports data from OCARINA II study of Ocrevus Genentech, a member of Roche, announced data from the Phase III OCARINA II study of Ocrevus, an investigational twice-yearly, 10-minute subcutaneous, or SC, injection. Results showed near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis which reinforce the potential benefits of this investigational formulation. Treatment with Ocrevus SC led to rapid and sustained B-cell depletion in the blood. The data will be presented as an oral presentation at the 76th American Academy of Neurology, or AAN, annual meeting taking place April 13-18 in Denver and has been recognized as an abstract of distinction by the AAN scientific committee. Updated, longer-term results showed that Ocrevus SC injection resulted in near-complete suppression of relapse activity and MRI up to 48 weeks with an ARR of 0.04, and most patients having no T1 gadolinium-enhancing lesions and no new/enlarging T2 lesions. These lesion types are markers of active inflammation and burden of disease, respectively. Additionally, in exploratory patient reported outcome measures patients reported a high level of satisfaction and convenience with Ocrevus SC injection. Additional data continued to show that the safety profile of Ocrevus SC injection was consistent with the well-established safety profile of Ocrevus IV infusion. No new safety signals were identified for Ocrevus SC. The most common adverse events in the Ocrevus SC group were injection reactions, including erythema, pain, swelling and pruritus, all of which were either mild or moderate and none of which led to treatment withdrawal. A total of seven serious AEs were experienced by three and four patients in the Ocrevus SC injection and IV infusion groups, respectively. The twice-yearly, 10-minute SC injection has the potential to expand the usage of Ocrevus to treatment centers without IV infrastructure or with IV capacity limitations. Data from the Phase III OCARINA II trial were submitted to health authorities around the world following the first presentation of these results during ECTRIMS-ACTRIMS 2023. Both the European Medicines Agency, or EMA, and FDA have accepted Genentech's submissions, with a target decision date of mid-2024 for the EMA and September 2024 for the FDA.
LMDXWILLBOOM
Posted - 3 days ago
I think us bagholders of $LMDX are basically on track. Roche can easily tweak the Cobas system to read the Lumiradx platform making Lumiradx the ultimate solution for PoC. I do not think Roche will get the razor instead they will get all the other devices on the Lumiradx platform (katalyst etc etc). Furthermore the pet diagnostics will also be readable through this network. We are sitting on a goldmine here and I'm all for it. We have little knowledge of what's going to happen but I'm sure with Roche's vision of collaborations & partnerships we may get multiple holdings of various big pharmas. I believe Roche will throw $rhhby our way while allowing us to keep Lumiradx I'm also under the assumption that the sale to Lonza was to pump into LumiraDx. Lumiradx will be appointed a new Roche hand picked CEO. I'm merely speculating, but these are highly probable outcomes.
LMDXWILLBOOM
Posted - 4 days ago
$LMDX I think they meant to say Lumiradx's $rhhby 🤨🧐🧐🧐
LMDXWILLBOOM
Posted - 4 days ago
$LMDX $rhhby Roche has been working on this project for a few years now. Advertising is a bit misleading as it's a series of various devices all housed under one network which will branch into pets as well. Katalyst diagnostics uses Lumiradx devices. So anything Roche diagnostics is doing will be adopted into this network. I guess they had to go with the "affordable moon act" to realize their affordable Healthcare initiatives with the aid of Bill Gates/The WHO/Lumiradx
javarich
Posted - 4 days ago
$LEAS $RHHBY $PFE yummy
LMDXWILLBOOM
Posted - 5 days ago
$LMDX https://youtu.be/V1fJiWH6eVI?si=xkaP4o8M1E96H5BS $rhhby wants to change healthcare around the globe! They want to collaborate on projects like Evinova $azn. Lumira has been liquidating the entire time based on mergers and such.
LMDXWILLBOOM
Posted - 1 week ago
$LMDX I figured the drop was liquidation. Strategic move on Lumiradx part to bring this into OTC during the liquidation process too. Means that they have something huge up their sleeve with $rhhby. Both parties are satisfied with this deal soooo.....bullish!
wwmeinc
Posted - 1 week ago
@jobix ...Thanks for the heads-up....interesting for sure....puts the spotlight on $ADAP a bit more closely...blood cancer treatments choices seem to be moving along lately....a $RHHBY / $IOVA tie-up would not be unexpected here given the mgmt background...as of Dec.31/23...Roche's cash on hand was appx ~12.5B.....Can not remember the last time biotech had a bidding war??....No matter, we have what big pharma needs today. Seems every Sunday night/Monday morning lately, has that 'sense' of, something ready to be announced :))....Thanks. glta https://www.biopharmadive.com/news/roche-genentech-adaptimmune-cancer-cell-therapy-deal-terminated/713076/
dhovekamp42
Posted - 1 week ago
@JoshThe3rd well in the longer run $ADAP will have to address the allogeneic T-cells platform development strategy again and short term they can no longer relax on continued yearly fees from $RHHBY
DonCorleone77
Posted - 1 week ago
$RHHBY $LLY Roche announces U.S. FDA granted BDD to its Elecsys pTau217 assay Roche (RHHBY) announced that its Elecsys pTau217 assay received Breakthrough Device Designation, BDD, from the U.S. Food and Drug Administration, FDA. This blood test, which is being developed in collaboration with Eli Lilly (LLY) and Company, will be used to help identify the presence or absence of amyloid pathology in individuals, which can help ensure they are able to receive appropriate care. "The incidence of dementia is growing worldwide, with 75 percent of cases remaining undiagnosed. Consequently, there is a critical role for Diagnostics to play in addressing this global health challenge," said Matt Sause, CEO of Roche Diagnostics. "We believe pTau217 is going to be crucial in the diagnosis of Alzheimer's disease, a condition where Roche Diagnostics is committed to improving the lives of patients worldwide. We plan to leverage our installed base of diagnostic systems, the largest in the world..."
groots
Posted - 1 week ago
$LMDX Today news, $RHHBY pushing for Sepsis , I guess $TT00 wasn't good enough
Lightningwithdayellahair
Posted - 1 week ago
$RHHBY I saw this air on Fox Business at around 6:05 pm and the representative from Prenosis said this was a 10 year partnership/ contract with Roche
See below;
Lightningwithdayellahair
Posted - 1 week ago
$RHHBY Tomorrow at 9:30am this is gonna FLY!!!!!!!
Lightningwithdayellahair
Posted - 1 week ago
$RHHBY Is this the company to make the new machines to detect sepsis? Prenosis ? Contracted by Roche to produce them ?
Grande4587258
Posted - 1 week ago
$RHHBY Tank .
Grande4587258
Posted - 1 week ago
$RHHBY pivot here .Strong Buy .
James_dean117
Posted - 1 week ago
$RHHBY probable acquisition target is $PRAX “100% of patients reached a complete response. That means all signs of the disease disappeared completely.” - Clinical trial results on PRAX epilepsy drug
treatments epilepsy ~ $3B - $5B annually
LMDXWILLBOOM
Posted - 1 week ago
$LMDX Seems like clockwork to me. $LZAGF >> $rhhby compound, Roche >> Lumiradx. To what extent Roche will go whoooo knows!
Hanse76
Posted - 2 weeks ago
@jmb_one any good and cheap stocks in switzerland available ? may be $RHHBY